Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose lithium carbonate for prevention of contrast-induced acute kidney injury
ChiCTR1900021798Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lithium carbonate in contrast-induced nephropathy (CIN) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Serum creatinine. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
lithium carbonate
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR1900021798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021798.